Skip to main content
. 2008 Sep 8;155(7):1093–1103. doi: 10.1038/bjp.2008.334

Figure 2.

Figure 2

Anti-CGRP antibodies block neurogenic vasodilatation in vivo. (a) CGRP-(8-37) (400 nmol kg−1, i.v.) blocked neurogenic vasodilatation in the dorsomedial skin of the rat hind paw 5 min after electrical stimulation (**P=0.01, n=10). (b) muMab 7E9 and muMab 4901 inhibited neurogenic vasodilatation in the dorsomedial skin of the rat hind paw as early as 30 min after injection (*P=0.05; **P=0.01). (c) muMab 4901 blocked neurogenic vasodilatation in the dorsomedial skin of the rat hind paw 7 days after treatment (*P=0.05; **P=0.01). (d) BIBN4096BS and muMab 7E9 blocked neurogenic vasodilatation of the middle meningeal artery (**P=0.01).